Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 9Phase 3 5Phase 1/2 3Phase NA 2Phase 4 2Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Breast Neoplasms 59Neoplasms 24Prostatic Neoplasms 21Multiple Myeloma 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 11Melanoma 9Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Pain, Postoperative 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Thyroid Neoplasms 5Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Pain 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4

Interventions

nilotinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Gastrointestinal Stromal Tumors × 1 year × Clear all
NCT01742299 2026-05-14

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Novartis

Phase 4 Completed
155 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00756509 2026-01-20

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Novartis

Phase 4 Completed
34 enrolled 11 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡